Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 5/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355022 | 0.85 | CHEK1 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGJAK3 | |
| SCHEMBL3070658 | 0.79 | CHEK1 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGJAK3 | |
| SCHEMBL4353898 | 0.79 | GSK3B (0.41) | JAK3BTKJAK2CHEK1KCNH2 | |
| SCHEMBL3069620 | 0.76 | JAK3 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGJAK3 | |
| SCHEMBL25298562 | 0.71 | HSD11B1 (0.40) | PIK3CDJAK3BTKJAK2 | |
| SCHEMBL25245764 | 0.71 | HSD11B1 (0.40) | PIK3CDJAK3BTKJAK2 | |
| SCHEMBL4354913 | 0.69 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGJAK3 | |
| SCHEMBL4349670 | 0.68 | CHEK1 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGJAK3 | |
| SCHEMBL4350214 | 0.68 | JAK3 (0.44) | PIK3CDPIK3CAPIK3CBPIK3CGJAK3 | |
| SCHEMBL2317595 | 0.68 | PTPN11 (0.39) | PIK3CDJAK3BTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | PIK3CD 218/4885PIK3CA 150/4885PIK3CB 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.